& #160; 0; 
Contact:
Edward Stiften, Chief Financial Officer
David Myers, Vice President Investor Relations
investor.relations@express-scripts.com
Express Scripts Reports a 43 Percent Increase in Adjusted Earnings Per Share
2007 Earnings Per Share Guidance Increased – Midpoint Reflects 39 Percent Growth
Record Third Quarter Cash Flow From Operations of $247 million
ST. LOUIS, October 24, 2007—Express Scripts, Inc. (Nasdaq: ESRX) announced third quarter net income of $142.9 million, or $0.56 per diluted share, which includes non-recurring charges totaling $0.04 per diluted share discussed below. Excluding these charges, diluted earnings per share was $0.60, a 43 percent increase over $0.42 per diluted share for the same quarter last year. All per share amounts have been adjusted to reflect the Company’s 2-for-1 stock split, which was effective June 22, 2007.
The Company reported cash flow from operations of $247.0 million in the third quarter compared to $158.8 million for the same period last year. During the quarter, Express Scripts repurchased 6.1 million shares of common stock for $313.6 million, and year to date, the Company has repurchased 23.1 million shares for $1,140.3 million.
“Our outstanding results demonstrate the power of aligning interests with plan sponsors and patients, which continues to fuel our success,” stated George Paz, president, chief executive officer and chairman. “Our industry-leading generic utilization rate reached a record 62.2 percent this quarter, and demonstrates the success of our business model.”
“We are entering the next stage of alignment: enabling better health and value at the consumer level. By unlocking value one member at a time, we are generating increased savings for our clients through lower-cost drugs and channels, and better health outcomes through improved therapy adherence. As we deliver savings for our clients, we deliver stronger performance for our stockholders.”
Third Quarter Review
Total adjusted claims for the quarter were 123.9 million. Retail network claims processed in the third quarter were 92.1 million, home delivery claims were 10.2 million, and Specialty and Ancillary Services (“SAAS”) claims were 1.2 million.
Gross profit for the third quarter increased 19 percent to $444.5 million from $374.3 million last year. The increase reflects higher generic utilization and lower retail and home delivery drug purchasing costs. Gross profit per adjusted claim was a record $3.59, a 20 percent increase over $2.99 for the same quarter last year.
During the third quarter, the Company recorded non-recurring charges of $18.5 million ($11.4 million net of tax), or $0.04 per diluted share in the SAAS segment, the majority of which pertained to a charge to bad debt expense resulting from the insolvency of a specialty distribution client. Adjusted operating income, excluding these non-recurring charges, increased 36 percent to $279.1 million from $205.7 million last year.
Adjusted operating income for the SAAS segment decreased $1.3 million sequentially from $10.5 million in the second quarter to $9.2 million in the third quarter due to the infusion line of business. The infusion line of business had an operating loss of $6.8 million for the quarter and $12.5 million for 9 months ended September 30, 2007. The Company recently announced plans to close 6 under-performing infusion sites and reduce overhead to improve the operating performance of this line of business. Concurrent with these changes, Express Scripts will evaluate the strategic fit of the infusion business in the Company’s product portfolio.
Operating income for the PBM segment increased 39 percent to $269.9 million from $194.0 million last year reflecting higher generic utilization and lower retail and home delivery drug purchasing costs. These same factors translated into strong EBITDA growth. Adjusted EBITDA increased 32 percent to $302.3 million from $229.5 million last year and reached a record $2.44 per adjusted claim, a 33 percent increase over $1.84 last year.
2007 Earnings Guidance
As a result of the strong underlying trends in the overall business, the Company is raising its previous 2007 diluted earnings per share guidance from a range of $2.23 to $2.29 to a range of $2.28 to $2.32. This guidance range excludes the non-recurring items identified in Tables 3 and 4 below. In addition, cash flow from operations is expected to be in the upper half of the previous guidance range of $750 million to $850 million.
Express Scripts, Inc. is one of the largest PBM companies in North America, providing PBM services to over 50 million members through thousands of client groups, including managed-care organizations, insurance carriers, employers, third-party administrators, public sector, workers compensation, and union-sponsored benefit plans.
Express Scripts provides integrated PBM services, including network-pharmacy claims processing, home delivery services, benefit-design consultation, drug-utilization review, formulary management, disease management, and medical- and drug-data analysis services. The Company also distributes a full range of injectable and infusion biopharmaceutical products directly to patients or their physicians, and provides extensive cost-management and patient-care services.
Express Scripts is headquartered in St. Louis, Missouri. More information can be found at http://www.express-scripts.com, which includes expanded investor information and resources.
This press release contains forward-looking statements, including, but not limited to, statements related to the Company’s plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements include but are not limited to:
| uncertainties associated with our acquisitions, which include integration risks and costs, uncertainties associated with client retention and repricing of client contracts, and uncertainties associated with the operations of acquired businesses |
| costs and uncertainties of adverse results in litigation, including a number of pending class action cases that challenge certain of our business practices |
| investigations of certain PBM practices and pharmaceutical pricing, marketing and distribution practices currently being conducted by various regulatory agencies and state attorneys general |
| changes in industry pricing benchmarks such as average wholesale price (“AWP”) and average manufacturer price (“AMP”) , which could have the effect of reducing prices and margins |
| increased compliance risk relating to our contracts with the DoD TRICARE Management Activity and various state governments and agencies |
| results in regulatory matters, the adoption of new legislation or regulations (including increased costs associated with compliance with new laws and regulations), more aggressive enforcement of existing legislation or regulations, or a change in the interpretation of existing legislation or regulations |
| uncertainties regarding the Medicare Part D prescription drug benefit, including the financial impact to us to the extent that we participate in the program on a risk-bearing basis, uncertainties of client or member losses to other providers under Medicare Part D, and increased regulatory risk |
| the possible loss, or adverse modification of the terms, of contracts with pharmacies in our retail pharmacy network |
| competition in the PBM and specialty pharmacy industries, and our ability to consummate contract negotiations with prospective clients, as well as competition from new competitors offering services that may in whole or in part replace services that we now provide to our customers |
| our ability to continue to develop new products, services and delivery channels |
| our ability to maintain growth rates, or to control operating or capital costs |
| uncertainties associated with U.S. Centers for Medicare & Medicaid’s (“CMS”) implementation of the Medicare Part B Competitive Acquisition Program (“CAP”), including the potential loss of clients/revenues to providers choosing to participate in the CAP |
| continued pressure on margins resulting from client demands for lower prices, enhanced service offerings and/or higher service levels, and the possible termination of, or unfavorable modification to, contracts with key clients or providers |
| the possible loss, or adverse modification of the terms, of relationships with pharmaceutical manufacturers, or changes in pricing, discount or other practices of pharmaceutical manufacturers or interruption of the supply of any pharmaceutical products |
| the use and protection of the intellectual property we use in our business |
| our leverage and debt service obligations, including the effect of certain covenants in our borrowing agreements |
| general developments in the health care industry, including the impact of increases in health care costs, changes in drug utilization and cost patterns and introductions of new drugs |
| increase in credit risk relative to our clients due to adverse economic trends or other factors |
| our ability to attract and retain qualified employees |
| other risks described from time to time in our filings with the SEC |
We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
EXPRESS SCRIPTS, INC.
Unaudited Consolidated Statement of Operations
| | Three Months Ended | | Nine Months Ended | |
| | September 30, | | September 30, | |
(in millions, except per share data) | 2007 | | 2006 | | 2007 | | 2006 | |
| | | | | | | | | | | | | |
Revenues 1 | $ | 4,519.0 | | | $ | 4,330.2 | | | $ | 13,658.9 | | | $ | 13,131.3 | | |
Cost of revenues 1 | | 4,074.5 | | | | 3,955.9 | | | | 12,344.9 | | | | 12,048.8 | | |
Gross profit | | 444.5 | | | | 374.3 | | | | 1,314.0 | | | | 1,082.5 | | |
| Selling, general and administrative | | 183.9 | | | | 168.6 | | | | 539.7 | | | | 500.8 | | |
| Operating income | | 260.6 | | | | 205.7 | | | | 774.3 | | | | 581.7 | | |
| Other (expense) income: | | | | | | | | | | | | | | | | |
Non-operating gains (charges), net | | 0.2 | | | | - | | | | (18.6 | ) | | | - | | |
Undistributed loss from joint venture | | (0.3 | ) | | | (0.4 | ) | | | (1.1 | ) | | | (1.2 | ) | |
Interest income | | 2.7 | | | | 2.3 | | | | 8.1 | | | | 11.3 | | |
Interest expense | | (31.3 | ) | | | (26.4 | ) | | | (79.1 | ) | | | (70.6 | ) | |
| | | (28.7 | ) | | | (24.5 | ) | | | (90.7 | ) | | | (60.5 | ) | |
| Income before income taxes | | 231.9 | | | | 181.2 | | | | 683.6 | | | | 521.2 | | |
| Provision for income taxes | | 89.0 | | | | 66.5 | | | | 254.3 | | | | 194.0 | | |
| Net income | $ | 142.9 | | | $ | 114.7 | | | $ | 429.3 | | | $ | 327.2 | | |
| | | | | | | | | | | | | | | | | |
| Basic earnings per share (“EPS”): | $ | 0.56 | | | $ | 0.42 | | | $ | 1.63 | | | $ | 1.16 | | |
| | | | | | | | | | | | | | | | | |
| Weighted average number of common shares | | | | | | | | | | | | | | | | |
outstanding during the period - Basic EPS | | 254.2 | | | | 272.2 | | | | 263.1 | | | | 282.4 | | |
| | | | | | | | | | | | | | | | | |
| Diluted earnings per share: | $ | 0.56 | | | $ | 0.42 | | | $ | 1.61 | | | $ | 1.14 | | |
| | | | | | | | | | | | | | | | | |
| Weighted average number of common shares | | | | | | | | | | | | | | | | |
outstanding during the period - Diluted EPS | | 257.3 | | | | 276.4 | | | | 266.3 | | | | 287.0 | | |
| | | | | | | | | | | | | | | | | |
1 Excludes estimated retail pharmacy co-payments of $909.4 million and $942.8 million for the three months ended September 30, 2007 and 2006, respectively, and $2,841.5 million and $3,209.2 million for the nine months ended September 30, 2007 and 2006, respectively. These are amounts we instructed retail pharmacies to collect from members. We have no information regarding actual co-payments collected.
EXPRESS SCRIPTS, INC. | |
Unaudited Consolidated Balance Sheet | |
| | | | | |
| | September 30, | | December 31, | |
(in millions, except share data) | 2007 | | 2006 | |
| Assets | | | | | | |
| Current assets: | | | | | | |
Cash and cash equivalents | $ | 96.0 | | | $ | 131.0 | | |
Receivables, net | | 1,308.4 | | | | 1,334.4 | | |
Inventories | | 158.8 | | | | 194.6 | | |
Deferred taxes | | 113.3 | | | | 90.9 | | |
Prepaid expenses and other current assets | | 19.6 | | | | 21.2 | | |
Total current assets | | 1,696.1 | | | | 1,772.1 | | |
| Property and equipment, net | | 203.9 | | | | 201.4 | | |
| Goodwill | | 2,689.5 | | | | 2,686.0 | | |
| Other intangible assets, net | | 350.9 | | | | 378.4 | | |
| Other assets | | 43.6 | | | | 70.2 | | |
Total assets | $ | 4,984.0 | | | $ | 5,108.1 | | |
| | | | | | | | | |
| Liabilities and Stockholders’ Equity | | | | | | | | |
| Current liabilities: | | | | | | | | |
Claims and rebates payable | $ | 1,203.8 | | | $ | 1,275.7 | | |
Accounts payable | | 547.2 | | | | 583.4 | | |
Accrued expenses | | 401.2 | | | | 390.2 | | |
Current maturities of long-term debt | | 240.1 | | | | 180.1 | | |
Total current liabilities | | 2,392.3 | | | | 2,429.4 | | |
| Long-term debt | | 1,740.3 | | | | 1,270.4 | | |
| Other liabilities | | 314.0 | | | | 283.4 | | |
Total liabilities | | 4,446.6 | | | | 3,983.2 | | |
| | | | | | | | | |
| Stockholders’ Equity: | | | | | | | | |
Preferred stock, 5,000,000 shares authorized, $0.01 par value per share; | | | | | | | | |
and no shares issued and outstanding | | - | | | | - | | |
Common stock, 1,300,000,000 shares authorized, $0.01 par value per share; | | | | | | | | |
shares issued: 318,875,000 and 159,442,000, respectively; | | | | | | | | |
shares outstanding: 252,044,000 and 135,650,000, respectively | | 3.2 | | | | 1.6 | | |
Additional paid-in capital | | 550.4 | | | | 495.3 | | |
Accumulated other comprehensive income | | 19.4 | | | | 11.9 | | |
Retained earnings | | 2,446.4 | | | | 2,017.3 | | |
| | | 3,019.4 | | | | 2,526.1 | | |
Common stock in treasury at cost, 66,831,000 and 23,792,000 | | | | | | | | |
shares, respectively | | (2,482.0 | ) | | | (1,401.2 | ) | |
Total stockholders’ equity | | 537.4 | | | | 1,124.9 | | |
Total liabilities and stockholders’ equity | $ | 4,984.0 | | | $ | 5,108.1 | | |
| | | | | | | | | |
